4.36  0.02 (0.46%)		11-07 16:00
Open: 4.2 High: 4.41 Volume: 3,859,240		Pre. Close: 4.34 Low: 4.15 Market Cap: 934(M)

Short term
Mid term
Targets	6-month :	6.71	1-year :	7.88
Resists	First :	5.75	Second :	6.75
Pivot price	5.51
Supports	First :	4.13	Second :	3.44
MAs	MA(5) :	4.76	MA(20) :	5.6
	MA(100) :	4.32	MA(250) :	2.72
MACD	MACD :	-0.2	Signal :	0
%K %D	K(14,3) :	5.7	D(3) :	5.1
RSI	RSI(14): 34.7
52-week	High :	6.75	Low :	1.14

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ATAI ] has closed above bottom band by 3.9%. Bollinger Bands are 119.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	4.42 - 4.45	4.45 - 4.48
Low:	4.08 - 4.12	4.12 - 4.15
Close:	4.3 - 4.36	4.36 - 4.41

Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

Wed, 05 Nov 2025
Latham & Watkins Advises atai Life Sciences in Strategic Combination With Beckley Psytech to Form AtaiBeckley - Latham & Watkins LLP

Wed, 05 Nov 2025
Atai Life Sciences N.V. (ATAI) Stock: Sharp Drop Follows Bold Merger Creating AtaiBeckley Biopharma Powerhouse - parameter.io

Wed, 05 Nov 2025
Atai Beckley files prospectus supplement for resale of 5.3 million shares - Investing.com Australia

Wed, 05 Nov 2025
ATAI Life Sciences Files Prospectus for Share Resale - TipRanks

Wed, 05 Nov 2025
Atai Beckley files prospectus supplement for resale of 5.3 million shares - Investing.com

Wed, 05 Nov 2025
atai Life Sciences and Beckley Psytech complete strategic combination to form AtaiBeckley - Proactive financial news

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Shares Out	0 (M)
Shares Float	267 (M)
Held by Insiders	1.6011e+008 (%)
Held by Institutions	6.9 (%)
Shares Short	17,790 (K)
Shares Short P.Month	0 (K)

EPS	-9.485e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-3 %
Return on Assets (ttm)	515 %
Return on Equity (ttm)	-29.6 %
Qtrly Rev. Growth	2.31e+006 %
Gross Profit (p.s.)	102.76
Sales Per Share	-48.12
EBITDA (p.s.)	1.45283e+006
Qtrly Earnings Growth	-0.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-76 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.1
Price to Cash Flow	10.19

Dividend	0
Forward Dividend	1.612e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.